UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $166
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo maintains a Neutral rating on Quest Diagnostics (NYSE:DGX) and raises the price target from $165 to $166.
October 23, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS analyst Kevin Caliendo maintains a Neutral rating on Quest Diagnostics and raises the price target from $165 to $166, indicating a slight positive outlook.
The Neutral rating suggests no strong buy or sell recommendation, but the slight increase in the price target from $165 to $166 indicates a marginally positive outlook. This may not significantly impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100